Psoriatic Arthritis Pipeline Insight

DelveInsight’s, “Psoriatic Arthritis– Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Psoriatic Arthritis Understanding

Psoriatic Arthritis: Overview

Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis. Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.

"Psoriatic Arthritis- Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines. The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Psoriatic Arthritis.

Psoriatic Arthritis Emerging Drugs Chapters

This segment of the Psoriatic Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Psoriatic Arthritis Emerging Drugs

ABT-494: AbbVie

Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. In August 2019, RINVOQ received U.S. Food and Drug Administration approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ also received approval by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Phase 3 trials of RINVOQ in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn’s disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.

Risankizumab: Abbvie

Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis.

Further product details are provided in the report……..

Psoriatic Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Psoriatic Arthritis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Psoriatic Arthritis

There are approx. 50+ key companies which are developing the therapies for Psoriatic Arthritis. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Registered include, Abbvie.

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Psoriatic Arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Psoriatic Arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Psoriatic Arthritis drugs.

Psoriatic Arthritis Report Insights

• Psoriatic Arthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Psoriatic Arthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Psoriatic Arthritis drugs?
• How many Psoriatic Arthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriatic Arthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Psoriatic Arthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriatic Arthritis and their status?
• What are the key designations that have been granted to the emerging drugs?